A universal standard for real-world evidence no longer seems quixotic. But how are companies going to do it?
Both pharma and payers say they need to talk more, but are they really listening?
With the access landscape shifting rapidly, pharma needs to watch its step
Universal standards for real-world evidence are closer than you might think